12/03/2018/by jnellisPoseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting
12/03/2018/by jnellisPoseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting
11/29/2018/by jcalhoonPoseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting
11/05/2018/by jcalhoonPoseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101
10/09/2018/by jcalhoonPoseida Therapeutics Appoints Marcy Graham as Vice President, Corporate Affairs
09/05/2018/by jcalhoonPoseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma
08/29/2018/by jcalhoonPoseida Therapeutics’ Clinical Update of BCMA-specific CAR-T Program Selected as a Late Breaking Presentation at the 4th Annual CAR-TCR Summit 2018
08/07/2018/by jcalhoonTeneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T Therapies
07/20/2018/by jcalhoonPoseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer
04/26/2018/by jcalhoonPoseida Therapeutics Presents Clinical Manufacturing Method for Durable, Persistent CAR-T Stem Cell Memory Therapies at World Orphan Drug Congress USA
